The Eppendorf BioFlo 120 bioprocess controller offers simplicity and ease of use, without sacrificing capability. No matter if you are in an academic, governmental or industrial research setting, the BioFlo 120 bioprocess controller is an attractive solution to meet your needs – all at an affordable price.
Servier acquires Kaerus Bioscience’s FXS candidate for US$450m
Latest NewsIn a US$450m deal with UK-based Kaerus Bioscience Ltd, Servier SA has acquired the development and commercialisation rights to KER-0193, a Phase II-ready drug candidate for the treatment of rare Fragile X syndrome, the most common monogenic cause of autism.
NRG Therapeutics Ltd bags £50m in Series B financing
Latest NewsBritish mitochondrial dysfunction specialist NRG Therapeutics Ltd. (“NRG”) has closed an oversubscribed £50m Series B financing. Funds will be used to to achieve clinical proof of concept in amyotrophic lateral sclerosis (ALS)/motor neurone disease (MND) and to generate Phase Ib data in Parkinson’s disease.
BioFlo® 120 – Performance Meets Value
ProductsThe Eppendorf BioFlo 120 bioprocess controller offers simplicity and ease of use, without sacrificing capability. No matter if you are in an academic, governmental or industrial research setting, the BioFlo 120 bioprocess controller is an attractive solution to meet your needs – all at an affordable price.
BioNTech‘s breast cancer ADC outperforms Roche’s Kadcyla
Latest NewsData on the primary endpoint of BioNTech’s/Duality Biologics’ pivotal Phase III study of its HER2 antibody-drug conjugate BNT323/DB-1303 are not yet public, However, BioNTech says that progression-free survival is better than with Roche’s second-line breast cancer therapy Kadcyla.
Alt protein: EASAC sees immediate need for action
Latest NewsExperts from the six science academies united in EASAC have called for the immediate establishment of a transparent framework across the EU for the production of biotechnologically manufactured meat alternatives.
Microbiome play MRM Health NV raises €55m in Series B
Latest NewsBelgian VIB spin-out MRM Health NV is using fresh funds raised in a €55m follow-on financing round to make its microbiome preparation MH002 licensable in an ongoing Phase IIb study for the indication ulcerative colitis. With €55m (US$64m) in Series B financing,
Novartis invests US$200min lacklustre Parkinson’s target
Latest NewsSwiss pharma major Novartis AG is investing money in the inhibition of the Parkinson’s target alpha-synuclein, which has already failed several times in clinical trials. The Swiss company is licensing the siRNA programme ARO-SNCA from Arrowhead Pharmaceuticals for US$200m.
Cytokinetics’ Aficamten with breakthrough Phase III results
Latest NewsCalifornia-based Cytokinetics Inc (CYTK) recorded a big jump in Nasdaq prices, at 40.45%, after presenting the results of its Phase III MAPLE-HCM study at the European Society of Cardiology Congress 2025.
Polpharma Biologics secures distribution of upcoming biosimilars
Latest NewsPolpharma Biologics SA and MS Pharma SA have signed licensing agreements for Polpharma’s vedolizumab (PB016), ocrelizumab (PB018) and guselkumab (PB019) biosimilars in the Middle East and North Africa (MENA) region.
Genentech inks US$400m IBD deal with OMass Therapeutics
Latest NewsThe US Roche unit Genentech Inc has signed a US$400 million licence deal with British NativeMS specialist OMass Therapeutics Ltd. Under the exclusive collaboration and licence agreement, Genentech intends to commercialise therapies for inflammatory bowel disease.